These results further support that Vandetanib lacks strong anti-proliferative capacity toward sporadic forms of MTC, which depend upon aberrant Cdk5 activity for proliferation and do not harbor known RET mutations. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.